LINZESS is approved as a once-daily treatment for functional constipation in paediatric patients between six and 17 years of age. Credit: Charlein Gracia on Unsplash.

The US Food and Drug Administration (FDA) has granted approval for Ironwood Pharmaceuticals’ LINZESS (linaclotide) as a once-a-day treatment for functional constipation in paediatric patients aged between six and 17 years.

Developed and marketed by AbbVie and Ironwood in the US, LINZESS was previously approved to treat irritable bowel syndrome with constipation or chronic idiopathic constipation in adult patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is the first and only prescription therapy to receive approval from the US FDA for functional constipation in paediatric patients.

Ironwood Pharmaceuticals CEO Tom McCourt stated: “Today, Ironwood has broken new ground again in the history of LINZESS, extending the clinical utility of our blockbuster treatment to six to 17-year-olds seeking relief for functional constipation, a debilitating condition.

“This approval is a momentous step forward in progressing our mission to advance the treatment of GI diseases and redefine the standard of care for GI patients and in ushering in a new era of growth for our company.”

The regulatory approval was based on the findings obtained from a double-blind, multi-centre Phase III trial conducted in 328 functional constipation patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Treatment with linaclotide demonstrated a statistically significant and clinically meaningful improvement in the 12-week spontaneous bowel movement (SBM) frequency rate against placebo.

They also showed a more than two-fold least squares mean [LSM – a statistical method used to find or estimate the numerical values of parameters to fit a function to a set of data] change from baseline to 2.6 SBMs per week versus 1.3 SBMs per week with placebo.